Evidence map›Paper›PMID 34621519›Full record

Trial reportF1000Research2021

Impact of ascorbic acid in reducing the incidence of vancomycin associated nephrotoxicity in critically ill patients: A preliminary randomized controlled trial.

Nouran Hesham El-Sherazy, Naglaa Samir Bazan, Sara Mahmoud Shaheen, Nagwa A Sabri

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nouran Hesham El-SherazyCritical Care Medicine Department, Cairo University Hospitals, Cairo University, 11562, Egypt.ORCID 0000-0001-7821-4349
Naglaa Samir BazanCritical Care Medicine Department, Cairo University Hospitals, Cairo University, 11562, Egypt.ORCID 0000-0002-8930-4697
Sara Mahmoud ShaheenClinical Pharmacy Department, Ain Shams University, Cairo, 11566, Egypt.
Nagwa A SabriClinical Pharmacy Department, Ain Shams University, Cairo, 11566, Egypt.
Ain Shams University · EGCairo University hospitals · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ascorbic AcidVancomycinAnti-Bacterial AgentsCritical IllnessHumansIncidenceKidneyProspective StudiesRetrospective StudiesRisk FactorsAnti-Bacterial AgentsAscorbic AcidVancomycinascorbic acidcritically ill patientsnephrotoxicityvancomycin

Identifiers

PMID34621519
PMCPMC8479849
OpenAlexW3201593991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.